184 related articles for article (PubMed ID: 17196268)
1. Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.
Loutfy MR; Raboud JM; Montaner JS; Antoniou T; Wynhoven B; Smaill F; Rouleau D; Gill J; Schlech W; Brumme ZL; Mo T; Gough K; Rachlis A; Harrigan PR; Walmsley SL
Antiviral Res; 2007 Jul; 75(1):58-63. PubMed ID: 17196268
[TBL] [Abstract][Full Text] [Related]
2. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
[TBL] [Abstract][Full Text] [Related]
3. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen.
Cabrera C; Marfil S; García E; Martinez-Picado J; Bonjoch A; Bofill M; Moreno S; Ribera E; Domingo P; Clotet B; Ruiz L
AIDS; 2006 Oct; 20(16):2075-80. PubMed ID: 17053353
[TBL] [Abstract][Full Text] [Related]
4. Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients.
Carmona R; Pérez-Alvarez L; Muñoz M; Casado G; Delgado E; Sierra M; Thomson M; Vega Y; Vázquez de Parga E; Contreras G; Medrano L; Nájera R
J Clin Virol; 2005 Mar; 32(3):248-53. PubMed ID: 15722032
[TBL] [Abstract][Full Text] [Related]
5. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
[TBL] [Abstract][Full Text] [Related]
6. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.
Aquaro S; D'Arrigo R; Svicher V; Perri GD; Caputo SL; Visco-Comandini U; Santoro M; Bertoli A; Mazzotta F; Bonora S; Tozzi V; Bellagamba R; Zaccarelli M; Narciso P; Antinori A; Perno CF
J Antimicrob Chemother; 2006 Oct; 58(4):714-22. PubMed ID: 16891628
[TBL] [Abstract][Full Text] [Related]
7. Short communication: high polymorphism rates in the HR1 and HR2 gp41 and presence of primary resistance-related mutations in HIV type 1 circulating in Brazil: possible impact on enfuvirtide efficacy.
Teixeira C; de Sá-Filho D; Alkmim W; Janini LM; Diaz RS; Komninakis S
AIDS Res Hum Retroviruses; 2010 Mar; 26(3):307-11. PubMed ID: 20334566
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.
Poveda E; Briz V; Paraskevis D; Barreiro P; Hatzakis A; Soriano V
AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1078-82. PubMed ID: 17919101
[TBL] [Abstract][Full Text] [Related]
9. HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.
Descamps D; Assoumou L; Masquelier B; Marcelin AG; Saidi S; Tamalet C; Cottalorda J; Plantier JC; Montes B; Izopet J; Peytavin G; Yerly S; Schneider V; Delaugerre C; Ferré V; Ruffault A; Pallier C; Morand-Joubert L; Chaix ML; Calvez V; Brun-Vézinet F; Costagliola D;
J Antimicrob Chemother; 2008 Sep; 62(3):451-5. PubMed ID: 18552344
[TBL] [Abstract][Full Text] [Related]
10. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
[TBL] [Abstract][Full Text] [Related]
11. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.
Charpentier C; Jenabian MA; Piketty C; Karmochkine M; Tisserand P; Laureillard D; Bélec L; Si-Mohamed A; Weiss L
Scand J Infect Dis; 2011 May; 43(5):373-9. PubMed ID: 21341978
[TBL] [Abstract][Full Text] [Related]
13. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.
Poveda E; Rodés B; Labernardière JL; Benito JM; Toro C; González-Lahoz J; Faudon JL; Clavel F; Schapiro J; Soriano V
J Med Virol; 2004 Sep; 74(1):21-8. PubMed ID: 15258964
[TBL] [Abstract][Full Text] [Related]
14. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
[TBL] [Abstract][Full Text] [Related]
15. Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C, and F isolates from Brazilian patients failing HAART.
Oliveira AC; Martins AN; Pires AF; Arruda MB; Tanuri A; Pereira HS; Brindeiro RM
AIDS Res Hum Retroviruses; 2009 Feb; 25(2):193-8. PubMed ID: 19239358
[TBL] [Abstract][Full Text] [Related]
16. gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure.
D'Arrigo R; Ciccozzi M; Gori C; Montieri S; Aquaro S; Bellagamba R; Boumis E; Di Perri G; Pizzi D; Antinori A; Rezza G; Perno CF
AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1296-302. PubMed ID: 17961119
[TBL] [Abstract][Full Text] [Related]
17. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.
Sista PR; Melby T; Davison D; Jin L; Mosier S; Mink M; Nelson EL; DeMasi R; Cammack N; Salgo MP; Matthews TJ; Greenberg ML
AIDS; 2004 Sep; 18(13):1787-94. PubMed ID: 15316339
[TBL] [Abstract][Full Text] [Related]
18. Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique.
Ismael N; Bila D; Mariani D; Vubil A; Mabunda N; Abreu C; Jani I; Tanuri A
AIDS Res Hum Retroviruses; 2014 Jun; 30(6):603-9. PubMed ID: 24188582
[TBL] [Abstract][Full Text] [Related]
19. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
[TBL] [Abstract][Full Text] [Related]
20. Functional characteristics of the natural polymorphisms of HIV-1 gp41 in HIV-1 isolates from enfuvirtide-naïve Korean patients.
Shin Y; Yoon CH; Yang HJ; Lim H; Choi BS; Kim SS; Kang C
Arch Virol; 2016 Jun; 161(6):1547-57. PubMed ID: 26997611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
